Skip to content

Inogen INGN Additional Paid-In Capital

Additional Paid-In Capital at other companies

Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
$17.58M+10.7%
Pulmonx Corporation logo
Pulmonx CorporationLUNG
$578.76M+3.8%
Savara logo
SavaraSVRA
$821.64M+23.7%
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
$1B+11.4%
ResMed logo
ResMedRMD

Other financials

Income statement

See full
Revenue$85.1M+3.4%
Gross profit$44.9M+1.7%
Operating income-$9.3M-21.9%
Net income-$8.3M-34.8%
EPS (diluted)-$0.30-20.0%

Balance sheet

See full
Cash & equivalents$93.1M-21.7%
Total debt$16.9M-11.9%
Total equity$182.9M-7.6%
Total assets$285.9M-7.3%

Cash flow

See full
Operating cash flow-$6.7M+60.2%
CapEx$210.0K-28.1%
Free cash flow-$6.9M+59.6%

Valuation

See full
Market cap$174.63M-9.7%
Enterprise value$98.45M-9.5%
P/S0.5×-0.1×

Profitability

See full
Gross margin52.8%-2.6pp
Operating margin-9.1%-0.8pp
Net margin-7.1%-0.8pp
FCF margin0.4%

Returns & leverage

See full
Return on equity-13.1%-0.9pp
Debt / equity0.1×0.0×
Current ratio3.1×0.0×

Where this comes from

Reported directly by Inogen in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Inogen’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inogen's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inogen's additional paid-in capital?
Inogen (INGN) reported additional paid-in capital of $363.37M in Q1 2026.
How has Inogen's additional paid-in capital changed year-over-year?
Inogen's additional paid-in capital increased by 1.7% year-over-year, from $357.45M to $363.37M.
What is the long-term trend for Inogen's additional paid-in capital?
Over 5 years (2020 to 2025), Inogen's additional paid-in capital has grown at a 5.9% compound annual growth rate (CAGR), from $273.52M to $363.55M.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.